ANDA 219865, held by Hetero Labs. Methotrexate Sodium.
As of Nov 21, 2026, ANDA 219865 (Methotrexate Sodium), held by Hetero Labs, was first approved by FDA on Apr 30, 2026, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 30, 2026 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Methotrexate SodiumEQ 50MG BASE/2ML (EQ 25MG BASE/ML) · injectable;injection | Methotrexate Sodium | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters